Relapsed or Refractory Acute Leukemia

Disease

Related News

Syndax Pharmaceuticals Expands Revuforj Access and Reports Strong Commercial Performance

Mar 19, 2026

Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.

Syndax Pharmaceuticals Expands Revuforj Access, Receives Price Target Increase

Feb 14, 2026

Syndax Pharmaceuticals partnered with World Orphan Drug Alliance to launch a Managed Access Program for Revuforj in multiple regions. A price target was raised to $28 while maintaining a Buy rating.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT03672851	Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia	TERMINATED	PHASE1